The increased prevalence of type 2 diabetes mellitus (T2DM) may cause an increase in chronic kidney disease burden.1 Sodium-glucose cotransporter 2 (SGLT2) inhibitors are used to lower blood glucose levels in patients with T2DM, and have been suggested to improve renal outcomes. The CREDENCE trial, ...

Self-monitoring blood glucose (SMBG) is an integral part of self-management in patients with type 1 diabetes. However, the use of SMBG in patients with type 2 diabetes has caused some debates in the field. A recent publication found a considerable amount of patients with type 2 diabetes not on insul...

The idea of combining glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist for reducing glycated hemoglobin A1c (HbA1c) and body weight has already been circulated for quite some time.1 Recently, a double-blind, randomized, phase 2 ...